Free Trial
NASDAQ:IKNA

Ikena Oncology (IKNA) Stock Price, News & Analysis

Ikena Oncology logo
$1.37 +0.02 (+1.48%)
As of 03:57 PM Eastern

About Ikena Oncology Stock (NASDAQ:IKNA)

Key Stats

Today's Range
$1.35
$1.42
50-Day Range
$1.08
$1.47
52-Week Range
$0.97
$1.94
Volume
46,783 shs
Average Volume
115,454 shs
Market Capitalization
$66.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00
Consensus Rating
Moderate Buy

Company Overview

Ikena Oncology Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
56th Percentile Overall Score

IKNA MarketRank™: 

Ikena Oncology scored higher than 56% of companies evaluated by MarketBeat, and ranked 451st out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Ikena Oncology has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Ikena Oncology has received no research coverage in the past 90 days.

  • Read more about Ikena Oncology's stock forecast and price target.
  • Earnings Growth

    Earnings for Ikena Oncology are expected to grow in the coming year, from ($0.91) to ($0.82) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Ikena Oncology is -1.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Ikena Oncology is -1.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Ikena Oncology has a P/B Ratio of 0.52. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Ikena Oncology's valuation and earnings.
  • Percentage of Shares Shorted

    0.39% of the float of Ikena Oncology has been sold short.
  • Short Interest Ratio / Days to Cover

    Ikena Oncology has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Ikena Oncology has recently increased by 0.75%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Ikena Oncology does not currently pay a dividend.

  • Dividend Growth

    Ikena Oncology does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.39% of the float of Ikena Oncology has been sold short.
  • Short Interest Ratio / Days to Cover

    Ikena Oncology has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Ikena Oncology has recently increased by 0.75%, indicating that investor sentiment is decreasing.
    • Insider Buying vs. Insider Selling

      In the past three months, Ikena Oncology insiders have not sold or bought any company stock.

    • Percentage Held by Insiders

      Only 5.94% of the stock of Ikena Oncology is held by insiders.

    • Percentage Held by Institutions

      75.00% of the stock of Ikena Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

    • Read more about Ikena Oncology's insider trading history.
    Receive IKNA Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for Ikena Oncology and its competitors with MarketBeat's FREE daily newsletter.

    IKNA Stock News Headlines

    Your Bank Account Is No Longer Safe
    What If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what the Department of Justice just admitted in court—claiming cash isn't legally your property. What does that mean? It means Washington thinks they can seize, freeze, or drain your accounts—whenever they want.
    William Blair Reaffirms Their Buy Rating on Ikena Oncology (IKNA)
    Ikena Oncology, Inmagene Biopharmaceuticals to Merge
    See More Headlines

    IKNA Stock Analysis - Frequently Asked Questions

    Ikena Oncology's stock was trading at $1.64 at the start of the year. Since then, IKNA stock has decreased by 16.5% and is now trading at $1.37.

    Ikena Oncology, Inc. (NASDAQ:IKNA) issued its quarterly earnings data on Thursday, May, 8th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.03.

    Ikena Oncology (IKNA) raised $125 million in an IPO on Friday, March 26th 2021. The company issued 7,800,000 shares at $15.00-$17.00 per share. Jefferies, Cowen, Credit Suisse and William Blair served as the underwriters for the IPO.

    Shares of IKNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

    Based on aggregate information from My MarketBeat watchlists, some other companies that Ikena Oncology investors own include Waste Connections (WCN), iShares Micro-Cap ETF (IWC), The RMR Group (RMR), DiamondRock Hospitality (DRH), American Water Works (AWK), AU Optronics (AUOTY) and Triple Flag Precious Metals (TFPM).

    Company Calendar

    Last Earnings
    5/08/2025
    Today
    7/08/2025
    Next Earnings (Estimated)
    8/14/2025
    Fiscal Year End
    12/31/2025

    Industry, Sector and Symbol

    Stock Exchange
    NASDAQ
    Sector
    Medical
    Industry
    MED - BIOMED/GENE
    Sub-Industry
    Pharmaceutical Products
    Current Symbol
    NASDAQ:IKNA
    CIK
    1835579
    Fax
    N/A
    Employees
    70
    Year Founded
    N/A

    Price Target and Rating

    High Price Target
    $4.00
    Low Price Target
    $2.00
    Potential Upside/Downside
    +119.0%
    Consensus Rating
    Moderate Buy
    Rating Score (0-4)
    2.50
    Research Coverage
    2 Analysts

    Profitability

    Trailing P/E Ratio
    N/A
    Forward P/E Ratio
    N/A
    P/E Growth
    N/A
    Net Income
    -$49.23 million
    Pretax Margin
    N/A

    Debt

    Sales & Book Value

    Annual Sales
    $9.16 million
    Price / Cash Flow
    N/A
    Book Value
    $2.61 per share
    Price / Book
    0.52

    Miscellaneous

    Free Float
    45,391,000
    Market Cap
    $66.12 million
    Optionable
    Not Optionable
    Beta
    0.50
    The 10 Best AI Stocks to Own in 2025 Cover

    Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

    Get This Free Report

    This page (NASDAQ:IKNA) was last updated on 7/8/2025 by MarketBeat.com Staff
    From Our Partners